{
    "clinical_study": {
        "@rank": "26878", 
        "arm_group": [
            {
                "arm_group_label": "TRV130 1.5 mg", 
                "arm_group_type": "Experimental", 
                "description": "TRV130 1.5 mg IV x 1 dose"
            }, 
            {
                "arm_group_label": "TRV130 3 mg", 
                "arm_group_type": "Experimental", 
                "description": "TRV130 3 mg IV x 1 dose"
            }, 
            {
                "arm_group_label": "TRV130 4.5 mg", 
                "arm_group_type": "Experimental", 
                "description": "TRV130 4.5 mg IV x 1 dose"
            }, 
            {
                "arm_group_label": "Morphine", 
                "arm_group_type": "Active Comparator", 
                "description": "Morphine 10 mg IV x 1 dose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Dextrose 5% in water IV x 1 dose"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to compare TRV130 to placebo and morphine to learn about its effects\n      on pain relief and side effects."
        }, 
        "brief_title": "Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Subjects", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Pain, Acute", 
        "detailed_description": {
            "textblock": "This  study will explore the pharmacokinetics, pharmacodynamics (PD), safety and\n      tolerability of TRV130."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent\n\n          -  Healthy adult males age 18 - 50 years, BMI 19-32 kg/m2\n\n          -  Acceptable duration of cold pain test results at screening\n\n        Exclusion Criteria:\n\n          -  Clinically significant medical illness or physical exam findings\n\n          -  Active dermatological conditions or skin trauma on the non-dominant hand, or\n             peripheral vascular disease\n\n          -  Partial blindness, keratoconus, nystagmus or any other ophthalmic condition which\n             could interfere with pupillometry\n\n          -  Use of tobacco or nicotine within 6 months prior to screening\n\n          -  History of recent (within 6 months) drug or alcohol abuse, as defined in DSM-IV-TR"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02083315", 
            "org_study_id": "CP130-1003"
        }, 
        "intervention": [
            {
                "arm_group_label": "TRV130 1.5 mg", 
                "description": "TRV130 1.5 mg IV x 1 dose", 
                "intervention_name": "TRV130 1.5 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TRV130 3 mg", 
                "description": "TRV130 3 mg IV x 1 dose", 
                "intervention_name": "TRV130 3 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TRV130 4.5 mg", 
                "description": "TRV130 4.5 mg IV x 1 dose", 
                "intervention_name": "TRV130 4.5 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Morphine", 
                "description": "Morphine 10 mg IV x 1 dose", 
                "intervention_name": "Morphine 10 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Dextrose 5% in water IV x 1 dose", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Morphine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "acute pain, analgesia, respiratory drive, ventilator response to hypercapnia, pupillometry", 
        "lastchanged_date": "March 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Salt Lake City", 
                    "country": "United States", 
                    "state": "Utah", 
                    "zip": "84106"
                }, 
                "name": "CRI Lifetree"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Explore the Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Adult Male Subjects", 
        "overall_official": {
            "affiliation": "Trevena Inc.", 
            "last_name": "David G Soergel, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Cold Pain Test", 
            "safety_issue": "No", 
            "time_frame": "8 hours postdose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02083315"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Ventilatory Response to Hypercapnia", 
                "safety_issue": "Yes", 
                "time_frame": "4 hours postdose"
            }, 
            {
                "measure": "Pupillometry", 
                "safety_issue": "No", 
                "time_frame": "8 hours postdose"
            }
        ], 
        "source": "Trevena Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Trevena Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}